Neurocrine Biosciences chief medical officer sells $222,636 in stock
Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold shares of the company's common stock. According to a recent SEC filing, Roberts sold 1,457 shares on January 31 at an average price ...
Neurocrine Biosciences officer sells $168,849 in stock
David W. Boyer, the Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company ...
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...
Unwanted hair starts growing on women's body, know causes and ways to prevent
Excessive hair growth can be embarrassing and frustrating. Learn the underlying causes of unwanted hair growth in women and ...
Yahoo Finance4 天
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital ...
(Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral ...